RxDoctor Payments Data

Victor Soriano, MD

Internal Medicine · Rockledge, FLNPI 1225463326

Payments from drug & device makers

$5,914in general payments, 2019–2025

Across 230 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$851
  • AstraZeneca$735
  • Novo Nordisk$655
  • GSK$542
  • Lilly USA, LLC$504
  • Amgen$436
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,80498%
  • Other$1102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,914 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$152,672
Medicare patients
373
Services billed
2,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$151,074
JardianceEmpagliflozin109$135,958
EliquisApixaban84$91,961
MounjaroTirzepatide61$78,183
EntrestoSacubitril/Valsartan35$39,908
FarxigaDapagliflozin Propanediol26$30,278
RybelsusSemaglutide13$29,269
XareltoRivaroxaban24$28,578
TrulicityDulaglutide20$21,900
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,176
JanuviaSitagliptin Phosphate13$14,062
Breo ElliptaFluticasone/Vilanterol21$13,710
MyrbetriqMirabegron17$10,895
JanumetSitagliptin Phos/Metformin Hcl11$10,635
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$10,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$655$180,343148 claims
Boehringer IngelheimJardiance$106$135,958109 claims
Lilly USA, LLCMounjaro, Trulicity$504$100,08381 claims
PfizerEliquis$83$91,96184 claims
NovartisEntresto$276$39,90835 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$542$38,24657 claims
AstraZenecaFarxiga$735$30,27826 claims
Johnson & JohnsonXarelto$851$28,57824 claims
AbbVieSynthroid$393$3,34343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →